Michael Elliot Hunt
Président chez Alliance for Advanced Therapies
Provenance du réseau au premier degré de Michael Elliot Hunt
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 25 | |
ReNeuron Ltd.
 ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom.
5
| Subsidiary | Biotechnology | 5 |
Alliance for Advanced Therapies
 Alliance for Advanced Therapies Medical/Nursing ServicesHealth Services The Alliance for Advanced Therapies’ mission is to improve the legislative, business and science climate for advanced therapies innovation in Europe. In order to do so, AAT promotes the interests of its members and the advanced therapies sector in Europe. AAT coordinates input to, and exchanges information with relevant European authorities. The Alliance also increases awareness of the sector among all relevant stakeholders, with a special focus on investors. Furthermore, AAT promotes increased funding for the sector from public and private sources.
1
| Subsidiary | Medical/Nursing Services | 1 |
ReNeuron (UK) Ltd.
 ReNeuron (UK) Ltd. BiotechnologyHealth Technology Part of ReNeuron Group Plc, ReNeuron (UK) Ltd. engages in research and experimental development on biotechnology. The company is based in Bridgend, UK and was founded in 2000.
1
| Subsidiary | Biotechnology | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Michael Elliot Hunt via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| Imperial College London | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
Simbec-Orion Group Ltd.
 Simbec-Orion Group Ltd. Pharmaceuticals: MajorHealth Technology Simbec-Orion Group Ltd. provides contract research services for rare and orphan conditions. The firm offers services for oncology, orphan diseases, respiratory, dermatology, infectious vaccines and diseases. The company was founded in 2014 and is headquartered in Pentrebach, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| ALLERGAN, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Excalibur Fund Managers Ltd.
 Excalibur Fund Managers Ltd. Investment ManagersFinance Excalibur Fund Managers Ltd (Excalibur) is a venture capital firm founded in 1996 by Christopher Evans. The firm is headquartered in London, United Kingdom. | Investment Managers | Founder Founder | |
Arix Capital Management Ltd.
 Arix Capital Management Ltd. Investment ManagersFinance Arix Capital Management Ltd (Arix Capital Management) is a venture capital subsidiary of Arix Bioscience Plc founded in 2012 by Christopher Thomas Evans. The firm is headquartered in Cardiff, United Kingdom. | Investment Managers | Director/Board Member Founder | |
Simbec Research Ltd.
 Simbec Research Ltd. Miscellaneous Commercial ServicesCommercial Services Simbec Research Ltd. provides clinical research service to pharmaceutical and biotechnology industries. It conducts drug trails for allergy, anti-infectives, cardiovascular, gastrointestinal, anti-inflammatory, oncology and respiratory. The firm also offers consultancy services, preparation of marketing authorization applications, and clinical trial applications. The company was founded in 1976 and is headquartered in Merthyr Tydfil, the United Kingdom. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
GlaxoSmithKline Services Unlimited
 GlaxoSmithKline Services Unlimited Pharmaceuticals: MajorHealth Technology Glaxosmithkline Services Unlimited Ltd. develops, manufactures and markets pharmaceutical products. The company was incorporated on March 23, 1972 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| King's College London | College/University | Corporate Officer/Principal Doctorate Degree | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer | |
| VERONA PHARMA PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| The University of Manchester | College/University | Undergraduate Degree Doctorate Degree | |
Zeneus Pharma Ltd.
 Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Medical Distributors | Founder Chief Tech/Sci/R&D Officer | |
| Antisoma Research Ltd. | Corporate Officer/Principal General Counsel | ||
EDX Medical Group Plc
 EDX Medical Group Plc Medical/Nursing ServicesHealth Services EDX Medical Group Plc engages in the provision of medical goods in the United Kingdom. It distributes Guardant Health’s cancer genomic tests for healthcare providers in Sweden, Denmark, Norway, Finland and Iceland (Nordics), also serving the private healthcare sector in the United Kingdom. The company was founded by Christopher Thomas Evans and Michael Hudson John on March 19, 2021 and is headquartered in Cambridge, the United Kingdom. | Medical/Nursing Services | Director/Board Member Founder | |
| WEIFA ASA | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| University of London | College/University | Doctorate Degree Graduate Degree | |
EDX Medical Ltd.
 EDX Medical Ltd. Medical/Nursing ServicesHealth Services Part of EDX Medical Group Plc, EDX Medical Ltd. is a British company that operates as a digital diagnostics. The company is based in Cambridge, UK. The company was founded by Christopher Thomas Evans. The CEO is Michael John Hudson. EDX Medical was acquired by TECC Capital Plc on November 14, 2022 for $6.88 million. | Medical/Nursing Services | Director/Board Member Founder | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chief Executive Officer Director of Finance/CFO | |
| SAREUM HOLDINGS PLC | Miscellaneous | Chairman Director/Board Member | |
| TIGENIX NV | Medical Specialties | Chief Executive Officer Director of Finance/CFO | |
| London Business School | College/University | Masters Business Admin Corporate Officer/Principal | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
| PHYSIOMICS PLC | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Jazz Pharmaceuticals UK Ltd.
 Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| MORPHIC HOLDING, INC. | Pharmaceuticals: Major | Director/Board Member | |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
HRA Pharma Development SARL
 HRA Pharma Development SARL Pharmaceuticals: MajorHealth Technology HRA Pharma Development SARL develops medicines and products for women's health and endocrinology. It offers emergency contraception, uterine fibroids, regular contraception, intimate health, genital herpes, and Lysosafe service. The company was founded by André Ulmann in 1996 and is headquartered in Châtillon, France. | Pharmaceuticals: Major | Director/Board Member | |
| INOZYME PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Royal College of General Practitioners
 Royal College of General Practitioners Other Consumer ServicesConsumer Services The Royal College of General Practitioners is a professional membership body for family doctors in the UK and overseas. The non-profit company is based in London, UK and has subsidiaries in the United Kingdom. The British company is committed to improving patient care and clinical standards. The RCGP offers a fellowship program, which is the highest level of membership and exemplifies their motto "cum scientia caritas". The company also provides accreditation for high-quality resources and activities relevant to general practitioners. The Daffodil Standards is a free, evidence-based framework to help practices self-assess and consistently offer the best end of life and bereavement care. The RCGP represents the interests of established GPs and acts as a conduit for local matters to be raised at national meetings. | Other Consumer Services | Corporate Officer/Principal | |
| KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman | |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member | |
European Biopharmaceutical Enterprises
 European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | Biotechnology | President | |
Eusa Pharma International Ltd.
 Eusa Pharma International Ltd. Pharmaceuticals: MajorHealth Technology Part of Jazz Pharmaceuticals Plc, Eusa Pharma International Ltd. is a Gibraltar specialty biopharmaceutical company that identifies, develops, and commercializes pharmaceutical products. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| NIOX GROUP PLC | Medical/Nursing Services | Director/Board Member | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Corporate Officer/Principal | |
| REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Smithkline Beecham Holdings Corp.
 Smithkline Beecham Holdings Corp. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Smithkline Beecham Holdings Corp. produces and distributes pharmaceutical products and dental healthcare products. The company is based in Wilmington, DE. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Nodenza, Inc. | Chief Tech/Sci/R&D Officer | ||
| SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Biotechnology | Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Neurocentrx Pharma Ltd.
 Neurocentrx Pharma Ltd. Pharmaceuticals: MajorHealth Technology Neurocentrx Pharma Ltd. is a British pharmaceutical company that manufactures and distributes medicines. The company is based in Edinburgh, UK. Neurocentrx Pharma was founded by Howard Marriage, Ronald M. Lindsay, and Carmel Reilly. Carmel Reilly has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
Athena Neurosciences LLC
 Athena Neurosciences LLC Miscellaneous Commercial ServicesCommercial Services Athena Neurosciences LLC operates as a research-based pharmaceutical company committed to the field of neurology. It develops therapeutic and diagnostic products. The company was founded by David Rowley-Jones, Larry C. Fritz, and Larry A. Bock in 1986 and is headquartered in Allegan, MI. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Neuro Foundation | Investment Trusts/Mutual Funds | Chairman | |
| INSEAD | College/University | Masters Business Admin | |
| Nerve Tumours Uk | Director/Board Member |
Statistiques
Internationale
| Royaume-Uni | 27 |
| Etats-Unis | 13 |
| France | 4 |
| Belgique | 3 |
| Danemark | 3 |
Sectorielle
| Health Technology | 27 |
| Consumer Services | 10 |
| Finance | 4 |
| Commercial Services | 4 |
| Health Services | 4 |
Opérationnelle
| Director/Board Member | 185 |
| Chairman | 65 |
| Corporate Officer/Principal | 63 |
| Independent Dir/Board Member | 37 |
| Founder | 29 |
Relations les plus connectées
| Insiders | |
|---|---|
| Christopher Evans | 62 |
| Simon Cartmell | 39 |
| Martin Edwards | 38 |
| Trevor Jones | 36 |
| John Berriman | 24 |
| Bryan Geoffrey Morton | 22 |
| Paul Harper | 20 |
| Timothy Corn | 20 |
| Michael Owen | 20 |
| Eduardo Bravo Fernández de Araoz | 19 |
| Mark James Docherty | 14 |
| Olav Hellebø | 13 |
| Richard Beckman | 12 |
| Claudia D'Augusta | 12 |
| Julian Howell | 8 |
- Bourse
- Insiders
- Michael Elliot Hunt
- Connexions Sociétés
